Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of CCX140-B in focal segmental glomerulosclerosis (FSGS)
2017-003021-15Phase 2Completed
- Sponsor
- ChemoCentryx
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ilacirnon in focal segmental glomerulosclerosis (FSGS) (3 arms), sponsored by ChemoCentryx. Primary endpoints: Safety and tolerability of CCX140-B and Effect of CCX140-B on renal function. Started Mar 2018; status: completed.
02
Drugs
ilacirnon
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2017-003021-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003021-15.